Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) and Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Inhibrx Biosciences and Voyager Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inhibrx Biosciences | 1 | 2 | 2 | 1 | 2.50 |
| Voyager Therapeutics | 1 | 0 | 1 | 1 | 2.67 |
Inhibrx Biosciences presently has a consensus target price of $197.50, suggesting a potential upside of 137.09%. Voyager Therapeutics has a consensus target price of $25.00, suggesting a potential upside of 1,345.09%. Given Voyager Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Voyager Therapeutics is more favorable than Inhibrx Biosciences.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Inhibrx Biosciences | N/A | -563.90% | -87.68% |
| Voyager Therapeutics | -416.32% | -63.42% | -49.40% |
Institutional and Insider Ownership
82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by insiders. Comparatively, 12.7% of Voyager Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Inhibrx Biosciences and Voyager Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Inhibrx Biosciences | $1.30 million | 943.21 | -$140.05 million | ($8.88) | -9.38 |
| Voyager Therapeutics | $40.37 million | 2.67 | -$119.72 million | ($1.73) | -1.00 |
Voyager Therapeutics has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Inhibrx Biosciences has a beta of 4.03, suggesting that its share price is 303% more volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.
Summary
Voyager Therapeutics beats Inhibrx Biosciences on 7 of the 13 factors compared between the two stocks.
About Inhibrx Biosciences
Inhibrx Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on developing biologic medicines for cancer and other serious diseases. Its research uses protein engineering to create investigational therapies designed to engage specific targets in the body. The company’s oncology pipeline has included INBRX-109, an antibody designed to activate the DR5 receptor and studied for chondrosarcoma, and INBRX-106, an investigational OX40-targeting antibody. These candidates are experimental and are not approved medicines.
About Voyager Therapeutics
Voyager Therapeutics is a biotechnology company developing genetic medicines for neurological diseases. Its work includes adeno-associated virus (AAV) gene therapies designed to deliver therapeutic genes to the nervous system. The company’s TRACER platform is used to discover and engineer AAV capsids, including candidates intended to cross the blood-brain barrier. Voyager has researched treatments for neurodegenerative and other neurological disorders and has partnered with pharmaceutical companies to advance gene therapy programs.
Receive News & Ratings for Inhibrx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
